Delivery Order SPE2DB24D2100-SPE2DB25FBEXM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $4,169.79. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an Indefinite Delivery Contract (IDC) mechanism. The order is due for completion by April 24, 2025, and will be performed at AmerisourceBergen's headquarters location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 24, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity, valued at $1,742.84. This firm fixed price delivery order, with an ultimate completion date of June 25, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and the product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $2,688.53. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor on a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 through December 2026, to supply Quillivant XR 25 mg/5 ml suspension in a 150ml quantity. This firm fixed-price delivery order, valued at $1,577.04, was competitively awarded without a set-aside designation and is scheduled for completion by July 31, 2025. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $1,314.20 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement with an ultimate completion date of June 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity, valued at $2,363.38. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX. The contract involved no set-aside designation and was...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBEXMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity, with a ceiling value of $3,058.06. This delivery order, which was competitively awarded with no set-aside designation, represents a firm fixed-price transaction executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania, with a completion date of June 26, 2025. Quillivant XR is an extended-release methylphenidate formulation used in the treatment of attention deficit hyperactivity disorder (ADHD), reflecting the broader pharmaceutical supply mission of the DLA Medical Supply Chain to support military healthcare systems and federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal vendor, maintains an extensive portfolio of delivery orders through its prime IDV with DLA, enabling the provision of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 6/25/25 |